| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥206.8B | ¥147.4B | +40.3% |
| Operating Income | ¥50.3B | ¥28.3B | +77.5% |
| Ordinary Income | ¥48.9B | ¥29.4B | +66.5% |
| Net Income | ¥34.7B | ¥20.5B | +69.0% |
| ROE | 11.4% | 7.4% | - |
FY2026 Q3 results show robust performance with Revenue 206.8B yen (YoY +40.3%), Operating Income 50.3B yen (+77.5%), Ordinary Income 48.9B yen (+66.5%), and Net Income 34.7B yen (+69.0%). The semiconductor testing device-related business, representing 99.2% of consolidated revenue, drove this expansion with segment revenue of 205.1B yen (+40.7% YoY) and segment operating income of 63.7B yen (+69.6% YoY), achieving a segment margin of 31.0%. Gross profit margin reached 43.6%, with operating margin expanding to 24.3% from prior year levels. Basic EPS increased 68.8% YoY to 274.34 yen. The equity ratio strengthened to 73.1% from 70.0% YoY, while cash and deposits grew to 132.4B yen.
Revenue expanded 40.3% YoY to 206.8B yen, primarily driven by the semiconductor testing device-related segment, which recorded 205.1B yen in revenue (+40.7% YoY). The Other segment contributed 1.7B yen with flat growth. This revenue acceleration reflects robust semiconductor industry demand and strong customer investment in testing equipment. Cost of sales increased 35.4% to 116.5B yen, resulting in gross profit of 90.2B yen and gross margin improvement to 43.6% from 41.6% in the prior year, indicating favorable product mix or pricing power. SG&A expenses rose 20.9% to 40.0B yen, growing slower than revenue and demonstrating operational leverage. Within SG&A, salaries increased 18.6% to 9.4B yen, while R&D expenses grew 11.3% to 12.2B yen (5.9% of revenue). Operating income surged 77.5% to 50.3B yen with operating margin expanding 4.3 percentage points to 24.3%.
Non-operating items contributed a net negative 1.3B yen to ordinary income. Non-operating income totaled 0.4B yen, comprising FX gains of 0.8B yen, interest income of 0.2B yen, and dividend income of 0.0B yen. Non-operating expenses of 1.8B yen included FX losses of 1.2B yen and interest expense of 0.4B yen, resulting in net FX impact of negative 0.4B yen. This led to ordinary income of 48.9B yen (+66.5% YoY), representing 23.7% ordinary margin. Extraordinary income of 1.2B yen was recorded during the period, described as subsidy income. After income tax expense of 15.5B yen (effective tax rate 30.8%), net income reached 34.7B yen (+69.0% YoY), yielding net profit margin of 16.8%. The performance pattern represents revenue up/profit up, with strong operating leverage driving profitability expansion across all profit levels.
The Semiconductor Testing Device-Related business generated revenue of 205.1B yen (+40.7% YoY) and operating income of 63.7B yen (+69.6% YoY), with segment margin of 31.0% representing a 5.6 percentage point improvement from 25.8% in the prior year. This segment constitutes 99.2% of consolidated revenue and is the core business. The Other segment, comprising electronic tube components, recorded revenue of 1.7B yen (flat YoY) and operating income of 0.1B yen (-25.0% YoY), with segment margin declining to 3.6% from 4.8%. Corporate costs not allocated to segments totaled 13.5B yen, up 44.5% from 9.3B yen in the prior year, primarily representing headquarters administrative functions. The material margin differential between segments highlights the high-value positioning of semiconductor testing products versus commodity electronic components. The dominant semiconductor testing segment's strong margin expansion indicates pricing power and favorable operating leverage in a capital-intensive business model.
[Profitability] ROE of 11.4% improved from 7.4% in the prior year (calculated using current period equity), driven by net profit margin expansion to 16.8% from 13.9% YoY and maintained asset turnover. Operating margin of 24.3% expanded 4.3 percentage points from 19.2% YoY, demonstrating strong operating leverage. Gross margin of 43.6% improved 2.0 percentage points from 41.6% YoY. R&D intensity of 5.9% reflects continued investment in technology development. [Cash Quality] Cash and deposits of 132.4B yen increased 9.0% YoY, providing coverage of 21.9x against short-term debt obligations of 6.1B yen (including current portion of bonds 1.0B yen and current portion of long-term loans 1.2B yen). Short-term investment securities of 0.4B yen supplement liquidity. Working capital shows cash conversion cycle of 304 days, with receivables turnover of 191 days, inventory turnover of 145 days, and payables turnover of 32 days. [Investment Efficiency] Total asset turnover of 0.50 reflects the capital-intensive nature of manufacturing operations. Property, plant and equipment of 112.1B yen includes construction in progress of 12.1B yen, indicating ongoing capacity expansion. [Financial Health] Equity ratio of 73.1% strengthened from 70.0% YoY, indicating conservative capital structure. Current ratio of 491.4% provides substantial liquidity cushion. Total debt of 48.0B yen (long-term loans 38.5B yen plus bonds 7.5B yen plus current portions 2.2B yen) represents modest leverage with debt-to-equity ratio of 0.16. Interest coverage ratio of 125.7x (operating income divided by interest expense) demonstrates strong debt servicing capacity.
Cash and deposits increased 11.0B yen YoY to 132.4B yen, reflecting profit accumulation despite working capital expansion. The balance sheet reveals retained earnings grew 25.8B yen to 230.3B yen, driven by net income of 34.7B yen partially offset by dividends. Working capital expansion is evident from trade receivables increasing 1.2B yen to 107.9B yen, while inventory components grew with raw materials up 2.4B yen to 21.8B yen, work in process up 1.8B yen to 17.8B yen, and finished goods up 0.4B yen to 6.6B yen. Trade payables decreased 5.9B yen to 10.1B yen, suggesting shortened payment cycles or supplier composition changes that consumed cash. Property, plant and equipment increased 5.8B yen to 112.1B yen with construction in progress rising 7.6B yen to 12.1B yen, indicating active capital investment. Long-term loans increased 1.0B yen to 38.5B yen, providing partial financing for expansion. The equity base strengthened with total equity growing 24.7B yen to 303.8B yen, primarily from profit retention. Cash coverage of current liabilities stands at 2.19x, maintaining strong short-term liquidity position.
Ordinary income of 48.9B yen compared to operating income of 50.3B yen reflects net non-operating cost of 1.3B yen, representing 0.6% of revenue. Non-operating income of 0.4B yen comprised primarily FX gains of 0.8B yen and interest income of 0.2B yen. Non-operating expenses of 1.8B yen included FX losses of 1.2B yen and interest expense of 0.4B yen, resulting in net FX impact of negative 0.4B yen. Non-recurring extraordinary income of 1.2B yen from subsidies contributed 2.4% to profit before tax, representing a temporary boost. Comprehensive income of 33.1B yen compared to net income of 34.7B yen shows negative other comprehensive income of 1.6B yen, primarily from foreign currency translation adjustments of negative 1.6B yen, reflecting yen appreciation against foreign operations. The 1.6B yen gap between net income and comprehensive income represents 4.6% of net income. Core operating profitability remains strong with operating income representing 87.0% of revenue before SG&A, indicating healthy earnings quality driven by business fundamentals rather than financial engineering or one-time gains.
Progress against full-year guidance shows revenue achievement of 73.6% (206.8B yen actual versus 281.0B yen full-year forecast), operating income of 77.4% (50.3B yen versus 65.0B yen forecast), and ordinary income of 78.9% (48.9B yen versus 62.0B yen forecast) through Q3. These progress rates exceed the standard 75% benchmark for Q3, suggesting the company is tracking ahead of its initial projections. Full-year forecasts imply Q4 revenue of 74.2B yen, operating income of 14.7B yen, and ordinary income of 13.1B yen. The Q4 implied margins of 19.8% operating margin and 17.7% ordinary margin would represent sequential deceleration from Q3's 24.3% operating margin, potentially reflecting conservative guidance or anticipated seasonal factors. The company revised its full-year forecast during the quarter, indicating management updated expectations based on strong Q3 performance. Full-year revenue growth guidance of 17.9% YoY and operating income growth of 41.8% YoY reflect sustained momentum in semiconductor testing demand, though growth rates moderate from Q3 actual performance of 40.3% and 77.5% respectively.
The company paid an interim dividend of 30 yen per share in Q2. Full-year dividend forecast of 50 yen per share consists of ordinary dividend of 35 yen and commemorative dividend of 5 yen, representing 20.0 yen increase from prior year's 30 yen. The dividend revision during the quarter reflects improved earnings outlook. Based on forecast EPS of 339.91 yen, the payout ratio would be 14.7%, indicating conservative capital allocation with substantial profit retention. Against actual Q3 cumulative EPS of 274.34 yen, the 50 yen annual dividend represents an 18.2% payout ratio. With net income of 34.7B yen for nine months and forecasted full-year net income of 43.0B yen, total annual dividends would approximate 6.3B yen (12.7M shares outstanding times 50 yen), yielding a 14.7% payout ratio against full-year forecast. No share buyback program was disclosed. The total return ratio equals the dividend payout ratio of approximately 14.7%, leaving 85.3% of earnings for reinvestment in business growth, debt reduction, or future shareholder returns. Retained earnings grew 25.8B yen to 230.3B yen, demonstrating management's preference for balance sheet strengthening and internal investment over aggressive shareholder distributions.
First, semiconductor industry cyclicality represents material revenue volatility risk given 99.2% concentration in semiconductor testing device business. Semiconductor capital equipment demand fluctuates with chip manufacturer investment cycles, and any downturn in semiconductor industry capex could materially impact revenue and profitability. Second, working capital management presents operational risk with receivables turnover at 191 days and inventory turnover at 145 days, creating cash conversion cycle of 304 days. This extended cycle ties up 146.0B yen in operating working capital and increases exposure to customer credit risk and inventory obsolescence. The 37.0% YoY decline in trade payables to 10.1B yen suggests potential supply chain financing pressure or shortened payment terms that could strain liquidity if revenue growth decelerates. Third, customer concentration risk exists in a specialized testing device market where limited semiconductor manufacturers drive demand, creating dependency on key customer relationships and their investment timing. Loss of major customers or delays in their capital expenditure programs would directly impact order flow and revenue visibility.
[Industry Position] (Reference - Proprietary Analysis) Profitability: Operating margin of 24.3% significantly exceeds the manufacturing industry median of 8.9% (IQR: 5.4%-12.7%), positioning the company in the top performance quartile. Net profit margin of 16.8% substantially outperforms the industry median of 6.5% (IQR: 3.3%-9.4%), reflecting superior pricing power and operational efficiency in the specialized semiconductor testing equipment segment. ROE of 11.4% exceeds the industry median of 5.8% (IQR: 3.1%-8.4%), demonstrating effective capital deployment. Financial Health: Equity ratio of 73.1% substantially exceeds the industry median of 63.8% (IQR: 49.1%-74.8%), indicating conservative capital structure with limited financial leverage. Current ratio of 491.4% significantly surpasses the industry median of 2.87x (IQR: 2.13x-3.84x), providing exceptional liquidity cushion. Efficiency: Revenue growth of 40.3% YoY substantially exceeds the industry median of 2.8% (IQR: -1.5%-8.8%), reflecting strong market positioning in semiconductor testing demand. Asset turnover of 0.50 aligns below the industry median of 0.56 (IQR: 0.41-0.65), consistent with capital-intensive manufacturing. Working capital turnover of 304 days compares unfavorably to the industry median of 112 days (IQR: 72-144 days), indicating room for improvement in cash conversion efficiency. Receivables turnover of 191 days significantly exceeds the industry median of 85 days (IQR: 69-117 days), suggesting extended customer payment terms or collection challenges. Industry: Manufacturing sector (105 companies), Comparison: FY2025-Q3 period, Source: Proprietary analysis.
First, the company demonstrates exceptional profitability with operating margin of 24.3% and net margin of 16.8%, both substantially exceeding manufacturing industry benchmarks by 2.7x and 2.6x respectively, driven by dominant market position in specialized semiconductor testing devices. This margin structure indicates sustainable competitive advantage and pricing power in a high-value niche market with significant barriers to entry. Second, balance sheet strength with 73.1% equity ratio, 491.4% current ratio, and 132.4B yen cash position provides substantial financial flexibility to fund growth investments, weather industry cyclicality, and potentially increase shareholder returns. The conservative 14.7% payout ratio leaves significant capacity for dividend growth or opportunistic share buybacks. Third, working capital management represents the primary operational concern, with 304-day cash conversion cycle significantly exceeding the industry median of 112 days. The 191-day receivables turnover suggests customer payment term extensions that could mask demand softness or credit quality deterioration. Trade payables declining 37.0% YoY to 10.1B yen may indicate supply chain financing pressure or strategic supplier relationship changes requiring monitoring. Fourth, business concentration in semiconductor testing devices creates cyclical volatility exposure, though current industry fundamentals remain strong as evidenced by 40.3% revenue growth. The transition from high Q3 growth to more moderate full-year guidance of 17.9% revenue growth suggests management anticipates normalization in coming quarters, warranting close monitoring of order trends and customer capex guidance.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.